• D Koukalová, R Reif, V Hájek, Z Mucha, J Veselý, M Viktorinová, and I Lochman.
• Institute of Microbiology, Medical Faculty, Palacky University, Olomouc, Czech Republic. koukalova@risc.upol.cz
• Bratisl Med J. 1999 May 1; 100 (5): 246-51.

AbstractThe authors present the results of the URVAKOL vaccine use in clinical practice. The vaccine was administered in the treatment of recurrent cystitis, persistent lower urinary tract infection, chronic pyelonephritis and prostatovesiculitis. The clinical efficacy of the vaccine was assessed by detection of bacteria and leukocytes in the urine, subjective complaints, skin tests and the assessment of selected specific and nonspecific immunity parameters in the urine and saliva. Significantly positive clinical and laboratory responses were observed in patients with uncomplicated cystitis. In the group of persistent urinary tract infections excellent responses were detected in one half of the patients. The remainder half stated disappearance of subjective complaints, but with persistence of pyuria or bacteriuria. Similar results of "improvement" were observed in 10 patients with chronic pyelonephritis. There were no changes of the clinical state observed in patients with chronic prostatitis. (Tab. 5, Fig. 2, Ref. 7.)

20 keywords...

hide…